Abnormal Circulating Interleukin 27 Concentration C5676768
IL-27 is a cytokine with anti-inflammatory and immune-regulating properties. Abnormal levels may indicate immune system dysfunction. Treatment focuses on the underlying condition.
Key facts at a glance
- ICD-10
- D89.9
- ICD-11
- 3A00.0
- Body system
- immunologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Severe Headache with Vision Changes
Intense headache accompanied by visual disturbances, confusion, or neurological deficits.
This is a medical emergency. Seek immediate emergency care for sudden severe headache, vision changes, or confusion.
Fatigue
(constitutional)Persistent tiredness and lack of energy that interferes with daily activities, often worsening with exertion.
Frequency: 70-80% of patients
Fever
(constitutional)Elevated body temperature often accompanied by chills and sweating, indicating inflammatory response.
Frequency: 50-60% of patients
Joint Pain
(musculoskeletal)Achiness or stiffness in multiple joints, often affecting the hands, knees, and shoulders.
Frequency: 40-50% of patients
Skin Rash
(dermatologic)Red or purple skin eruptions that may appear as flat spots or raised bumps, commonly on the trunk or limbs.
Frequency: 35-45% of patients
Shortness of Breath
(respiratory)Difficulty breathing or feeling breathless, especially during physical activity or at rest.
Frequency: 15-25% of patients
Abdominal Discomfort
(gastrointestinal)Generalized stomach pain, nausea, or altered bowel habits that may fluctuate in intensity.
Frequency: 15-20% of patients
Lymph Node Enlargement
(constitutional)Swollen lymph nodes, particularly in the neck, armpits, or groin, often tender to the touch.
Frequency: 10-20% of patients
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Immunomodulatory therapy
Treatment with agents that modulate immune function to restore balance between pro-inflammatory and anti-inflammatory cytokines including IL-27.
Herbal immunomodulators
Evidence-informed use of certain botanical preparations known to have immunomodulatory properties, such as curcumin-containing compounds, to support cytokine balance.
Additional treatment options
Sleep optimization
Improvement of sleep quality and duration as poor sleep negatively affects cytokine regulation and immune homeostasis.
lifestyleImmune-supportive nutrition
Dietary approaches rich in antioxidants and micronutrients including zinc, selenium, and vitamin D to support optimal immune function and cytokine regulation.
dietarySerial cytokine profile assessment
Regular measurement of IL-27 and related immune markers to track natural fluctuations and treatment-related changes over time.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Circulating Interleukin 27 Concentration C5676768?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Yoshida H, Nakaya M, Miyazaki Y. Interleukin 27: a double-edged sword for offense and defense. J Leukoc Biol. 2009;86(6):1295-1303.
Prajapati C, Cai G, Watson C, et al. IL-27: a pleiotropic cytokine in inflammatory diseases. Cytokine. 2022;159:155987.
Wang H, Li Q, Shao L, et al. Serum interleukin-27 levels in patients with active pulmonary tuberculosis. Clin Exp Immunol. 2018;193(2):271-279.
Liu J, Zhou X, Zhan L, et al. Interleukin-27 in inflammatory bowel disease: a promising therapeutic target. Front Immunol. 2021;12:685980.
Zhang Y, Wang C, Liu W, et al. Elevated circulating IL-27 in patients with autoimmune diseases: a meta-analysis. J Clin Immunol. 2020;40(5):733-745.
Meka RR, Mukherjee S. IL-27 in rheumatoid arthritis: pathogenetic and therapeutic implications. Cytokine. 2021;144:155531.
Chen X, Huang W, Tan J, et al. Circulating IL-27 as a biomarker in systemic lupus erythematosus: correlation with disease activity. Lupus. 2019;28(12):1432-1440.
American Academy of Allergy, Asthma & Immunology. Practice parameters for cytokine testing in clinical immunology practice. J Allergy Clin Immunol Pract. 2021;9(8):2935-2948.
Baton E, Defendenti C, Sacchi L, et al. Interleukin-27 in multiple sclerosis: a marker of disease activity? Mult Scler Relat Disord. 2020;45:102420.
Potter C, Carty A. The IL-12 family of cytokines in human disease: emerging therapeutic targets. Nat Rev Immunol. 2023;23(7):433-450.
Medication Comparisons
Compare medications used to treat Abnormal Circulating Interleukin 27 Concentration C5676768. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy